Peter Davies, the 2015 Recipient of the Potamkin Award, Joins the Scientific Advisory Board of QR Pharma

QR Pharma Receives US Patent 8,691,864 to Treat Dementia

QR Pharma Begins Collaboration on Posiphen® and Huntington’s Disease

QR Pharma Announces the Appointment of New Chairman and New Board Member

QR Pharma CEO Maria Maccecchini receives Women Entrepreneur award

Posiphen® Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice

QR Pharma Presents at the University of Pennsylvania: Convergence of Factors Leading to Neurodegenerative Disorders

QR Pharma announces the start of a phase I clinical study for Bisnorcymserine , First human trial of compound discovered at NIH may treat Alzheimer’s disease

QR Pharma to Present at the Alzheimer’s Association International Conference

QR Pharma to Present at 11th Annual World Pharma Congress